Primary enuresis in adults: pathogenesis, clinical course and modern approaches to treatment: A review

Cover Page

Cite item

Full Text

Abstract

The review article presents current data on the epidemiology, classification, pathogenesis, risk factors, diagnosis, and features of the clinical course of primary enuresis in adults. The main methods of treatment of patients with primary enuresis are described in detail. It has been shown that in the treatment of this category of patients, the leading role is given to the use of a synthetic analogue of the antidiuretic hormone desmopressin. A detailed analysis of the pharmacological properties and clinical use of desmopressin in patients with primary enuresis is presented. The advantages of prescribing a sublingual form of desmopressin, which ensures its high efficiency and good tolerability of therapy.

About the authors

Igor V. Kuzmin

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN-code: 2684-4070
Scopus Author ID: 56878681300

D. Sci. (Med.), Pavlov First Saint Petersburg State Medical University

Russian Federation, Saint Petersburg

References

  1. Nevéus T, von Gontard A, Hoebeke P, et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Report from the Standardisation Committee of the International Children’s Continence Society. J Urol. 2006;176(1):314-24. doi: 10.1016/S0022-5347(06)00305-3
  2. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol. 2001;165(6Pt. 1):1914-7. doi: 10.1097/00005392-200106000-00017
  3. Гусева Н.Б., Никитин С.С., Корсунский А.А., и др. Результаты многоцентрового исследования по диагностике немоносимптомного энуреза у детей в различных регионах РФ. Педиатрия. 2019;98(2):107-12 [Guseva NB, Nikitin SS, Korsunskiy AA, et al. Results of a multicenter study on the diagnosis of nonmonosymptomatic enuresis in children in various regions of the Russian Federation. Pediatria. 2019;98(2):107-12 (in Russian)]. doi: 10.24110/0031-403X-2019-98-2-107-112
  4. Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol. 2002;36(5):354-62. doi: 10.1080/003655902320783863
  5. Buckley BS, Lapitan MC. Prevalence of urinary and faecal incontinence and nocturnal enuresis and attitudes to treatment and help-seeking amongst a community-based representative sample of adults in the United Kingdom. Int J Clin Pract. 2009;63(4):568-73. doi: 10.1111/j.1742-1241.2008.01974.x
  6. Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int. 2004;93(3):341-5. doi: 10.1111/j.1464-410x.2003.04612.x
  7. Никитин С.С., Гусева Н.Б., Колодяжная А.В., и др. Enuresis nocturna у детей и подростков: обзор современной литературы и перспективы лечения с использованием десмопрессина. Педиатрия им. Г.Н. Сперанского. 2020;99(3):265-27 [Nikitin SS, Guseva NB, Kolodyazhnaya AV, et al. Enuresis nocturna in children and adolescents: a review of contemporary literature and treatment perspectives using desmopressin. Pediatria n.a. GN. Speransky. 2020;99(3):265-70 (in Russian)]. doi: 10.24110/0031-403X-2020-99-3-265-270
  8. Levine A. Enuresis in the navy. Am J Psychiatry. 1943;100:320-5.
  9. Hirasing RA, van Leerdam FJ, Bolk-Bennink L, Janknegt RA. Enuresis nocturna in adults. Scand J Urol Nephrol. 1997;31(6):533-6. doi: 10.3109/00365599709030657
  10. Baek M, Park K, Lee HE, et al. Korean Children's Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: population based cross sectional study. J Korean Med Sci. 2013;28(7):1065-70. doi: 10.3346/jkms.2013.28.7.1065
  11. Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315-20. doi: 10.1007/s00192-016-3099-0
  12. Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Where is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43(4):401-6. doi: 10.1097/WON.0000000000000234
  13. Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down Syndrome. Neurourol Urodyn. 2017;36(6):1550-6. doi: 10.1002/nau.23146
  14. Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8(3):217-22. doi: 10.1007/s11884-013-0193-8
  15. Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9(2):84-9. doi: 10.1007/s11884-014-0237-8
  16. Akhavizadegan H, Locke JA, Stothers L, Kavanagh A. A comprehensive review of adult enuresis. Can Urol Assoc J. 2018;13(8):282-7. doi: 10.5489/cuaj.5485
  17. Rittig S, Lassen Schaumburg H, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179(6):2389-95. doi: 10.1016/j.juro.2008.01.171
  18. Бирюкова Е.В., Шинкин М.В. Центральный несахарный диабет: этиопатогенез, подходы к диагностике и лечению. Эффективная фармакотерапия. 2021;17(26):38-48 [Biryukova YeV, Shinkin MV. Central Diabetes Insipidus: Etiopathogenesis, Approaches to Diagnosis and Treatment. Effective Pharmacotherapy. 2021;17(26):38-48 (in Russian)]. doi: 10.33978/2307-3586-2021-17-26-38-48
  19. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3):1021-5. doi: 10.1097/01.ju.0000136203.76320.f6
  20. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. doi: 10.1016/S0090-4295(02)02243-4
  21. Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Expert Opin Pharmacother. 2018;19(3):291-8. doi: 10.1080/14656566.2018.1429406
  22. Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23(2):175-82. doi: 10.1097/GME.0000000000000517
  23. Шорманов И.С., Соловьев А.С., Тюзиков И.А., Куликов С.В. Анатомо-физиологические и патофизиологические особенности нижних мочевых путей в гендерном и возрастном аспектах. Урологические ведомости. 2021;11(3):241-56 [Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St-Petersburg). 2021;11(3):241-56 (in Russian)]. doi: 10.17816/uroved70710
  24. Шорманов И.С., Куликов С.В., Соловьев А.С. Особенности компенсаторно-адаптационных реакций сосудистого русла мочевого пузыря мужчин пожилого и старческого возраста в условиях гиперплазии предстательной железы. Урологические ведомости. 2022;12(2):127-35 [Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology reports (St-Petersburg). 2022;12(2):127-35 (in Russian)]. doi: 10.17816/uroved108475
  25. Abeygunasekera AM, Jayasinghe RJ, Duminda MT, et al. Significance of recent onset nocturnal enuresis in adult men: a prospective study. Ceylon Med J. 2004;49(3):79-81. doi: 10.4038/cmj.v49i3.3244
  26. Madhu CK, Hashim H, Enki D, Drake MJ. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36(1):188-91. doi: 10.1002/nau.22912
  27. Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря. Дис. … д-ра мед. наук. СПб., 2007 [Kuz'min IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyria: Dis. … d-ra med. nauk. Saint Petersburg, 2007 (in Russian)].
  28. D’Ancona CAL, de Moraes Lopes MHB, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31(5):634-6. doi: 10.1002/nau.21195
  29. Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171(6Pt2):2595-8. doi: 10.1097/01.ju.0000112790.72612.0a
  30. Katz EG, MacLachlan LS. Nocturnal Enuresis in the Adult. Curr Urol Rep. 2020;21(8):31. doi: 10.1007/s11934-020-00983-2
  31. Lee D, Dillon BE, Lemack GE. Adult Onset Nocturnal Enuresis: Identifying Causes, Cofactors and Impact on Quality of Life. Low Urin Tract Symptoms. 2018;10(3):292-6. doi: 10.1111/luts.12183
  32. Weiss JP, Everaert K. Management of Nocturia and Nocturnal Polyuria. Urology. 2019;133:24-33. doi: 10.1016/j.urology.2019.09.022
  33. Sinha R, Raut S. Management of nocturnal enuresis – myths and facts. World J Nephrol. 2016;5(4):328-38. doi: 10.5527/wjn.v5.i4.32
  34. Läckgren G, Hjälmås K, van Gool J, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999;88(6):679-90. doi: 10.1080/08035259950169396
  35. Yucel S, Kutlu O, Kukul E, Baykara M. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64(5):1020-5. doi: 10.1016/j.urology.2004.06.067
  36. Vandersteen DR, Husmann DA. Treatment of primary nocturnal enuresis persisting into adulthood. J Urol. 1999;161(1):90-2. doi: 10.1016/S0022-5347(01)62073-1
  37. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009;74(4):915-9. doi: 10.1016/j.urology.2009.05.033
  38. Neveus T. Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol. 2011;26(8):1207-14. doi: 10.1007/s00467-011-1762-8
  39. Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты. РМЖ. Медицинское обозрение. 2021;5(5):273-9 [Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian)]. doi: 10.32364/2587-6821-2021-5-5-273-279
  40. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;1:120-5 [Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;1:120-5 (In Russian)]. doi: 10.18565/urology.2021.1.120-125
  41. Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты. Урологические ведомости. 2020;10(2):163-71 [Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St-Petersburg). 2020;10(2):163-71 (in Russian)]. doi: 10.17816/uroved102163-171
  42. Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты. Клиническая геронтология. 2021;27(11-12):21-34 [Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11-12):21-34 (in Russian)]. doi: 10.26347/1607-2499202111-12021-034
  43. Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10(10):CD012059. doi: 10.1002/14651858.CD012059.pub2
  44. F-MELT® – система вспомогательных веществ для производства таблеток, диспергируемых в ротовой полости (ODT). Фармацевтическая отрасль. 2015;6(53):68-9 [F-MELT® – sistema vspomogatel'nykh veshchestv dlia proizvodstva tabletok, dispergiruemykh v rotovoi polosti (ODT). Farmatsevticheskaia otrasl'. 2015;6(53):68-9 (in Russian)].
  45. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-60. doi: 10.1111/j.1742-1241.2007.01493.x
  46. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction. J Urol. 2011;185(6):2308-13. doi: 10.1016/j.juro.2011.02.039
  47. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-11. doi: 10.1177/0091270006291838
  48. Vande Walle JGJ, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97(3):603-9. doi: 10.1111/j.1464-410X.2006.05999.x
  49. Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235-42. doi: 10.1007/s00431-013-1992-9
  50. Проспективное открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем®, таблетки подъязычные 240 мкг (ЗАО «Канонфарма продакшн», Россия), и Минирин®, таблетки подъязычные 240 мкг («Ферринг АГ», Швейцария) у здоровых добровольцев после однократного приема натощак. Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Ссылка активна на 01.11.2022 [Prospektivnoe otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem®, tabletki pod"iazychnye 240 mkg (ZAO «Kanonfarma prodakshn», Rossiia) i Minirin®, tabletki pod"iazychnye 240 mkg («Ferring AG», Shveitsariia) u zdorovykh dobrovol'tsev posle odnokratnogo priema natoshchak Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/158-20.03.2017.html. Accessed: 01.11.2022 (in Russian)].
  51. Открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Ноурем® таблетки, 0,2 мг (ЗАО «Канонфарма Продакшн», Россия), и Минирин® таблетки, 0,2 мг («Ферринг АБ», Швеция). Режим доступа: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Ссылка активна на 01.11.2022 [Otkrytoe randomizirovannoe perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Nourem® tabletki, 0,2 mg (ZAO «Kanonfarma Prodakshn», Rossiia), i Minirin® tabletki, 0,2 mg («Ferring AB», Shvetsiia). Available at: https://clinline.ru/reestr-klinicheskih-issledovanij/906-23.04.2012.html. Accessed: 01.11.2022 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Chronological classification of adult bedwetting.

Download (43KB)
Indexing metadata
3. Fig. 2. Clinical classification of adult bedwetting.

Download (38KB)
Indexing metadata
4. Fig. 3. Mechanism of urine retention at night.

Download (78KB)
Indexing metadata
5. Fig. 4. Treatment of bedwetting in adults.

Download (173KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies